Olivia Mitchell
Question:212. Deputy Olivia Mitchell asked the Minister for Health the annual cost per patient for the supply of Kalydeco, the cystic fibrosis drug; and if he will make a statement on the matter. [19529/13]
View answerThursday, 25 April 2013
Questions (212)
Written answers
Dr. James Reilly TD, Minister for Health announced, on the 1st February 2013, that Kalydeco, a new innovative medicine for the treatment of cystic fibrosis (CF) in patients who have the G551D mutation, would be made available for patients in Ireland from the 1st of March. The projected costs for the provision of Kalydeco to patients was estimated at over €234,000 per patient per annum in the assessment carried out by the National Centre for Pharmacoeconomics. Following successful confidential commercial negotiations between the HSE and the manufacturer, a mechanism was agreed whereby the drug could be made available to patients while at the same time significantly reducing the budget impact of the drug. The treatment cost per patient per annum is commercially confidential.